The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study / Spagnuolo, Vincenzo; Galli, Laura; Bigoloni, Alba; Nozza, Silvia; Monforte, Antonella d'Arminio; Antinori, Andrea; Di Biagio, Antonio; Rusconi, Stefano; Guaraldi, Giovanni; Di Giambenedetto, Simona; Lazzarin, Adriano; Castagna, Antonella. - In: JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. - ISSN 1758-2652. - STAMPA. - 17:(2014), pp. 19806-19806. [10.7448/IAS.17.4.19806]
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
GUARALDI, Giovanni;
2014
Abstract
The 48-week interim analysis of the MODAT study showed that confirmed virologic failure (CVF) was more frequent in patients simplifying to ATV/r monotherapy compared to maintaining ATV/r-based triple therapy. The DSMB recommended stopping study enrollment but continuing follow-up of enrolled patients. We present the 96-week efficacy analysis.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Spagnuolo_et_al-2014-Journal_of_the_International_AIDS_Society.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
233.43 kB
Formato
Adobe PDF
|
233.43 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
